Japan’s PMDA Collecting Adverse Event Reports Directly From Patients
This article was originally published in PharmAsia News
Japan's pharmaceutical regulatory agency says its pilot program for patient reports on adverse drug reactions has been running smoothly with minor changes underway.
You may also be interested in...
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.
New rules separate medical devices from pharma regulations to provide clarity and regulatory efficiency, removing approval hurdles for devices and software in 2014.
Novartis Pharma in Japan established a compliance advisory board as part of a move to salvage its tarnished image with ongoing Diovan scandals.